Low-Risk Bladder Cancer Rarely Progresses to Muscle Invasion

Low-Risk Bladder Cancer Rarely Progresses to Muscle Invasion
Low-Risk Bladder Cancer Rarely Progresses to Muscle Invasion

(HealthDay News) -- Low-risk bladder cancer rarely progresses to muscle invasion but is associated with an increased risk of disease-specific mortality compared with matched populations, according to research published in the March issue of The Journal of Urology.

Kate D. Linton, of the University of Sheffield in the United Kingdom, and colleagues examined the risk of disease-specific mortality in 699 patients with primary, low-risk, noninvasive (G1pTa) bladder cancer who were followed for a median of 61 months.

During follow-up, the researchers found that 17 patients died of bladder cancer, including 13 of 14 who displayed progression to muscle invasion and four of 19 who exhibited grade progression to high-grade, nonmuscle invasive disease. Tumor weight and low-grade dysplasia in the initial resection specimen were found to be significantly associated with disease-specific mortality. In these patients, the rate of disease-specific mortality was five times higher than in age and gender matched general populations.

"The rate of progression to muscle invasion and disease-specific mortality in patients with low-risk bladder cancer is low but higher than in the general population," the authors write. "Current surveillance regimens failed to detect advancing disease in time to alter its natural history. While a randomized trial is necessary to robustly confirm our findings, these observations question current surveillance regimens."

One author disclosed a financial tie to GlaxoSmithKline; the study was partially supported by a GlaxoSmithKline SK Clinician Scientist fellowship.

Abstract
Full Text (subscription or payment may be required)

This article originally appeared here.

Related Resources

close

Next Article in Male Reproductive Cancers

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Male Reproductive Cancers

Outcomes Similar Despite Timing of Prostatectomy

Outcomes Similar Despite Timing of Prostatectomy

Outcomes are similar between men with histologically comparable prostate cancer who undergo watchful waiting versus immediate surgery.

Replacing Carbs with Vegetable Fat May Reduce Prostate CA Mortality

Replacing Carbs with Vegetable Fat May Reduce Prostate ...

Replacement of 10% of carbohydrates with vegetable fat cuts the incidence of lethal prostate cancer and death from the disease.

African-Americans Wait Longer to be Treated for Prostate CA

African-Americans Wait Longer to be Treated for Prostate ...

African-Americans have longer waits from time of diagnosis of prostate cancer to treatment compared with Caucasian patients.